Pharmaceutical companies are funding global obesity awareness campaigns, prompting scrutiny over whether these initiatives blur the lines with prohibited prescription drug advertising. In Switzerland, where direct-to-public ads for prescription medicines are banned, companies like Eli Lilly have launched campaigns using billboards and online platforms with slogans such as "obesity is not your fault." While these campaigns do not explicitly name specific drugs or treatment methods, regulators are investigating for potential indirect promotion. Swissmedic is examining Eli Lilly's campaign, and similar investigations have occurred in Spain and France, where Eli Lilly and Novo Nordisk faced fines. Experts and regulators emphasize the delicate balance between raising disease awareness and avoiding unauthorized promotion, particularly when companies are among the few offering treatments for a condition.